<DOC>
	<DOCNO>NCT02162537</DOCNO>
	<brief_summary>The patient carry complicate primary lung cancer brain metastases die less 3 month delay disease absence treatment . The median survival patient approximately six month treatment associate radiotherapy chemotherapy base cisplatin standard treatment . In study patient die brain disease one case two , likely patient require brain irradiation ( prognosis case link extra-cerebral disease ) . The benefit patient group B ( without systematic irradiation ) suffer side effect radiation . The risk group see brain metastasis become symptomatic . The role cerebral radiotherapy patient treat chemotherapy unclear : patient irradiate systematically ( since `` reference '' treatment involved aim obtain good control brain lesion maintain well neurological status ) patient show cerebral progression irradiate ( avoidance possibly useless brain radiotherapy side effect ) . The aim study well determine position cerebral radiotherapy context . Main objective : determine whether difference term progression-free survival therapeutic strategy initial systematic brain radiotherapy follow chemotherapy cis-platine/alimta + / - Bevacizumab strategy initial chemotherapy cis-platine/alimta + / - Bevacizumab associate brain radiotherapy case cerebral progression patient NSCLC asymptomatic brain metastasis</brief_summary>
	<brief_title>Therapeutic Strategies Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases</brief_title>
	<detailed_description>This trial compare two strategy aim determine best place cerebral radiotherapy ( initially systematic progression ) . Arm A : Initial cerebral radiotherapy chemotherapy , standard arm Arm B : Chemotherapy Radiotherapy brain clinical radiological cerebral progression , experimental arm ( The chemotherapy treatment standard treatment use drug authorization indication )</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Patients histologically cytologically proven nonepidermoid , nonsmall cell lung cancer , nonEGFR ( Epidermal Growth Factor Receptor ) mutate ( mutation test impracticable ) . 2 . Patients brain metastasis/metastases without neurosurgical indication . 3 . Asymptomatic patient ( without treatment stable steroid antiepileptic treatment ≥ 5 day prior obtain baseline MRI brain , ≥ 5 day prior first dose study treatment ( Cycle 1 , Day 1 ) . 4 . At least one lesion measurable accord RECIST ( Response Evaluation Criteria Solid Tumors ) criterion . 5 . ECOG ( Eastern Cooperative Oncology Group ) Performance Status 0 1 6 . No previous chemotherapy cancer , apart adjunctive chemotherapy 18 month ago . 7 . Prior surgery authorize case document recurrence progression . 8 . Adequate biological function ( hematologic , platelet , hemoglobin , hepatic function , alkaline phosphatase , ASAT ( Aspartate transaminase ) ALAT ( Alanine Aminotransferase ) ; creatinine clearance ) . 9 . For woman : Effective contraception woman childbearing age treatment 6 month follow treatment . For men : They must surgically sterile accept use effective contraception 6 month treatment period . 10 . Patients 18 year age . 11 . Estimated survival least 12 week . 12 . Consent sign patient 1 . Patients present brain lesion eligible curative treatment ( neurosurgical ) . 2 . Symptomatic brain metastasis/metastases spite symptomatic treatment . 3 . Epidermoid carcinoma . 4 . Con indication Bevacizumab furthermore 5 . Patients present brain lesion eligible curative treatment ( neurosurgery radiosurgery ) . 6 . Symptomatic brain metastasis/metastases spite symptomatic treatment . 7 . Epidermoid carcinoma . 8 . Cons indication Bevacizumab 9 . Inability take folic acid vitamin B12 vitamin supplementation dexamethasone premedication ( equivalent corticosteroid ) , inability comply study procedure . 10 . History cancer , exception cervical cancer situ , skin cancer melanoma , adequately treat lowgrade prostatic cancer ( Gleason score &lt; 6 ) , unless cancer diagnose treat 5 year ago without sign recurrence . 11 . Patients present systemic disorder , investigator 's opinion , compromise participation study reason relate treatment safety compliance . 12 . Patients incapable discontinue aspirin treatment dose &gt; 1300 mg/day nonsteroidal antiinflammatory treatment two day day , day two day day administration pemetrexed ( Alimta ) . 13 . Patients present 3rd sector ( pleural effusion , ascites ) clinically detectable uncontrollable simple measure evacuatory puncture type treatment inclusion study . 14 . Patients present neuropathy grade &gt; 2 accord criterion CTC ( Common toxicity Criteria ) v3.0 . 15 . Patients whose foreseeable compliance geographical distance render monitor difficult . 16 . Pregnant breastfeed woman . 17 . Significant weight loss ( ≥ 10 % ) 6 week precede inclusion study . 18 . Vaccination yellow fever within 30 day precede inclusion study . 19 . Consindication take steroid 20 . Persons deprive liberty result judicial administrative decision 21 . Concomitant participation another trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Strategy</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Cisplatin</keyword>
</DOC>